Algene goes hunting for Alzheimer's genes
This article was originally published in Clinica
Executive Summary
Algene Biotechnologies has granted Montreal University a Can$5.3 million research grant to clone and sequence Alzheimer's disease genes. The genes lie somewhere in five chromosomal regions linked to early-onset Alzheimer's disease during a founder population study (populations with a limited number of ancestors in their recent history). The work will be carried out at the university's geriatric care unit at the Centre Hospitalier Cote-des Neiges.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.